WASHINGTON, June 7, 2017 /PRNewswire/ --
The Society of Interventional Oncology (SIO), a global
organization working to nurture and support interventional oncology
worldwide, and global specialist healthcare company BTG plc
announce their 2017 Interventional Oncology / Immuno-Oncology
research grant recipients.
(Logo:
http://photos.prnewswire.com/prnh/20150805/255981LOGO )
The grant recipients will be recognised in the welcoming address
at the World Congress of Interventional Oncology in Boston on 8th June, 2017.
The investigators and project proposals that have been awarded
grants are:
Rafael Duran, MD
Centre Hospitalier Universitaire Vaudois
Investigating the Immunobiology of Hepatocellular Carcinoma
in Patients Undergoing Y90
Radioembolization
Joseph P. Erinjeri, MD,
PhD
Memorial Sloan Kettering Cancer Center
T-Cell Clonality and Cancer Neoantigen Presentation Following
Interventional Oncology (IO) Therapies: Which IO Techniques
Optimally Stimulate the Immune System?
Florian J. Fintelmann,
MD
Massachusetts General Hospital
A Pilot Study of Cryoablation Combined with Immune Checkpoint
Inhibitor Therapy in Patients with PD-1 Refractory Metastatic
Melanoma: Prospective Clinical Research and Correlative Laboratory
Studies
Stephen Hunt, MD, PhD
University of Pennsylvania
TAEVax: Immunobiologic Treatment Effects of Embolization in a
Rat HCC Model
"We are very pleased that through the generosity of BTG, SIO has
been able to fund the most meritorious, cutting-edge research that
combines the strengths of interventional oncology and
immuno-oncology-two disciplines that hold great promise for
improving cancer therapy. The large number of high quality
submissions to this grant call attests to the intense interest of
interventional oncologists worldwide to continue to advance our
field through robust scientific inquiry and clinical study," stated
S. Nahum Goldberg, MD, SIO
Interventional/Immuno-oncology Working Group Chair, and Vice-Chair
for Research and Head of the Interventional Oncology Unit, Hadassah
Hebrew University Medical Center in
Jerusalem, Israel.
Melanie Lee, Chief Scientific
Officer of BTG, added "We're pleased to be working with the SIO to
advance scientific knowledge in this area of medicine. The
projects selected by the SIO Interventional/Immuno-oncology Working
Group will extend understanding of the role of the immune system in
interventional oncology therapy, the interplay between
loco-regional and immunotherapies, and underlying mechanisms of
stimulating immunity to fight cancer."
The Interventional Oncology / Immuno-Oncology research grant
program was established earlier this year to fund initiatives that
evaluate how interventional oncology therapies stimulate the immune
system; combine loco-regional and immunotherapy approaches to
improve clinical outcome; and improve the understanding of the
underlying mechanisms that cause different therapies to influence
adaptive and innate immunity, as well as underlying inflammation
and tumorigenesis.
Grant recipients were chosen by the SIO Interventional Oncology
/ Immuno-Oncology Working Group, which includes both interventional
radiologists and immuno-oncologists. The Working Group plans to
publish a white paper later this year to guide further research and
clinical practice.
About Society of Interventional Oncology (SIO)
SIO serves as the only membership-based organization dedicated
wholly to the emerging field of Interventional Oncology (IO),
working to establish, nurture, and support IO as the fourth pillar
of cancer therapy alongside medical, surgical, and radiation
oncology worldwide. IO therapies, such as embolization and tumor
ablation, combine the expertise of oncology and radiology and use
imaging technology to diagnose and treat localized cancers in ways
that are precisely targeted and minimally or non-invasive. The
society hosts the annual World Conference for Interventional
Oncology (WCIO). For more information, please visit:
www.sio-central.org
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: www.btgplc.com
For further information contact:
SIO
Amanda Winger O'Kane, Marketing
& Communications
+1-202-367-1164
aokane@sio-central.org
BTG
Chris Sampson, Corporate
Communications Director
+44-(0)-20-7575-1595
Mobile: +44-(0)-7773-251-178